2013 Kompletní literatura ALERGOLOGIE, PNEUMOLOGIE

ACTA MEDICINAE 2/2013 Kompletní literatura ALERGOLOGIE, PNEUMOLOGIE 2

Alergologie a klinická imunologie v roce 2013

2

Patogeneze chronické obstrukční plicní nemoci a možnosti protizánětlivé léčby

3

Atopický ekzém – co nového v léčbě?

3

Kontaktní ekzém – kontaktní alergeny

4

Léčba atopické dermatitidy v přehledu

4

Role vitaminu D u chronických zánětlivých onemocnění

4

Doporučené postupy v léčbě astmatu bronchiale

5

Rinosinusitidy: od praktického lékaře do specializované péče ORL nebo alergologie?

5

Využití salinických roztoků v léčbě onemocnění horních cest dýchacích

5

Kardiovaskulární bezpečnost indakaterolu v léčbě chronické obstrukční plicní nemoci

6

Novinky v léčbě karcinomu plic

7

Chronická obstrukční plicní nemoc

7

Flutikazon furoát v léčbě alergické rýmy

7

Léčba pacienta IFN-β-1b (Betaferonem)

7

Využití certolizumab pegolu v léčbě aktivní revmatoidní artritidy

8

Účinná léčba abataceptem v první linii u pacientky s diabetem mellitem I. typu a s revmatoidní artritidou

8

Subkutánní interferon beta-1a v léčbě roztroušené sklerózy

8

Systémová léčba osteolýzy indukované nádorem

9

Antitrombotická léčba – léčba apixabanem

9

Novinky ve fekální bakterioterapii

prof. MUDr. Václav Špičák, CSc. Immuno-flow, s. r. o., Praha, Česká iniciativa pro astma, o. p. s. MUDr. Jan Chlumský, Ph.D. Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha

Prim. MUDr. Štěpánka Čapková Dermatologické oddělení pro děti, FN Motol, Praha RNDr. Dana Nováková Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol, Praha doc. MUDr. Eliška Dastychová, CSc. I. dermatovenerologická klinika LF MU a FN u sv. Anny v Brně MUDr. Radek Litvik Kožní oddělení FN Ostrava

MUDr. Jana Čepová, Ph.D., MBA | MUDr. Margareta Beyerová | Ing. Eva Klapková, Ph.D. | Ing. Marta Pechová | prof. MUDr. Richard Průša, CSc. Ústav lékařské chemie a klinické biochemie, 2. LF UK a FN v Motole, Praha MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha MUDr. Jan Pokorný, CSc. DG Centrum Ostrava, ORL

MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha

Prim. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie Nemocnice Na Bulovce a 3. LF UK Praha

prof. MUDr. Jana Skřičková, CSc. | MUDr. Marcela Tomíšková | MUDr. Bohdan Kadlec | MUDr. Lenka Jakubíková, Ph.D. | MUDr. Jana Špaldová Klinika nemocí plicních a tuberkulózy LF MU a FN Brno doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz LF a PF MU Brno MUDr. Lucie Cwiková Městská nemocnice Ostrava-Fifejdy MUDr. Ester Seberová RESPIRAL, s. r. o., Plzeň

MUDr. Magdaléna Hladíková, Ph.D. Neurologická klinika LF MU a FN Brno MUDr. David Suchý, PhD. Oddělení klinické farmakologie FN Plzeň

MUDr. Petr Kopsa Revmatologické a rehabilitační oddělení Thomayerovy nemocnice, Praha

MUDr. Iva Okáčová | doc. MUDr. Pavel Štourač, Ph.D. Neurologická klinika LF MU a FN Brno, CEITEC – Středoevropský technologický institut MU Brno MUDr. Simona Paulíková | prof. MUDr. Jiří Petera Ph.D. | MUDr. Adam Paulík LF UK a Klinika onkologie a radioterapie FN Hradec Králové MUDr. Hynek Poul Oddělení hematologie a transfuziologie Nemocnice Pelhřimov, p. o. prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

Alergologie a klinická imunologie v roce 2013 prof. MUDr. Václav Špičák, CSc. Immuno-flow, s. r. o., Praha, Česká iniciativa pro astma, o. p. s. 1 Blahoš, J. – Ticháček, B.: STOROČENKA, historie České lékařské společnosti J. E. Purkyně, ČLS JEP, 2005. 2 Špičák, V.: Genetika alergie. In: Petrů, V.: Dětská alergologie, Mladá fronta, 2012, s. 35. 3 Špičák, V.: Etiopatogeneze alergie. In: Petrů, V.: Dětská alergologie, Mladá fronta, 2012, s. 66. 4 Bochner, B. B., et al.: Advances in mechanisms of allergy and clinical imunology in 2012. J Allergy Clin Immunol, 2013, v tisku. 5 Kauffmann, F. – Demenais, F.: Gene-environment interactions in asthma and allergic diseases: Challenges and perspectives. JACI, 2012, 130, s. 1229–1240. 6 Yang, I. V. – Schwarz, D. A.: Epigenetic mechanisms and the

development of asthma. JACI, 2012, 130, s. 1243–1255. 7 Choy, D. F., et al.: Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. The Journal of Immunology, 2011, 186, s. 1861–1869. 8 Woodruff, P. C., et al.: T-helper type 2-driven inflammation defines major subphenotypes of asthma. American J of Respiratory and Critical Care Medicine, 2009, 180, s. 388–395. 9 Von Gunten, S., et al.: Update in clinical allergy and immunology. Allergy, 2012, 67, s. 1491–1500. 10 Soyer, O. U., et al.: Mechanisms of peripheral tolerance to allergens. Allergy, 2013, 68, s. 161–170. 11 Špičák, V.: České stopy v alergologii. Alergie, 2012, 14, s. 246–250.

Patogeneze chronické obstrukční plicní nemoci a možnosti protizánětlivé léčby MUDr. Jan Chlumský, Ph.D. Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha 1 Bateman, E. D. – Rabe, K. F. – Calverley, P. M. A. – Goehring, U. M. – Brose, M. – Bredenbroker, D., et al.: Roflumilast with long-acting + 2-agonists for COPD: influence of exacerbation history. European Respiratory Journal, 2011, 38, s. 553–560. 2 Bourdin, A. – Burgel, P.-R. – Chanez, P. – Garcia, G. – Perez, T. – Roche, N.: Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. European Respiratory Review, 2009, 18, s. 198–212. 3 Burgel, P.-R. – Bourdin, A. – Chanez, P. – Chabot, F. – Chaouat, A. – Chinet, T., et al.: Update on the roles of distal airways in COPD. European Respiratory Review, 2011, 20, s. 7–22. 4 Calverley, P. – Rabe, K. – Goehring, U. – Kristiansen, S. – Fabbri, L. – Martinez, F., et al.: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet, 2009, 374, s. 685–694. 5 Celli, B. R. – MacNee, W. – Agusti, A. – Anzueto, A. – Berg, B. – Buist, A. S., et al.: Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J, 2004, 23, s. 932–946. 6 Fabbri, L. – Calverley, P. – Izquierdo-Alonso, J. – Bundschuh, D. – Brose, M. – Martinez, F., et al.: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet, 2009, 374, s. 695–703. 7 Gibson, G.: Pulmonary hyperinflation a clinical overview. Eur Respir J, 1996, 9, s. 2640–2649. 8 Gibson, G.: Lung volumes and elasticity. Clin Chest Med, 2001, 22, s. 623–635. 9 Grootendorst, D. C. – Gauw, S. A. – Verhoosel, R. M. – Sterk, P. J. – Hospers, J. J. – Bredenbroker, D., et al.: Reduction in sputum

neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Torax, 2007, 62, s. 1081–1087. 10 Hatzelmann, A. – Morcillo, E. – Lungarella, G. – Adnot, S. – Sanjar, S. – Beume, R., et al.: The preclinical pharmacology of roflumilast—a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther, 2010, 23, s. 235–256. 11 McIvor, R. A.: Future options for disease intervention: Important advances in phosphodiesterase 4 inhibitors. European Respiratory Review, 2007, 16, s. 105–112. 12 O‘Donnell, D. – Laveneziana, P.: Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev, 2006, 15, s. 61–67. 13 O‘Donnell, D. – Laveneziana, P.: The clinical importance of dynamic lung hyperinflation in COPD. COPD, 2006, 3, s. 219–232. 14 O‘Donnell, D. – Webb, K.: Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis, 1993, 148, s. 1351–1357. 15 O´Donnell, D. E. – Bredenbroker, D. – Brose, M. – Webb, K. A.: Physio logical effects of roflumilast at rest and during exercise in COPD. European Respiratory Journal, 2012, 39, s. 1104–1112. 16 Rabe, K.: Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev Resp Med, 2010, 4, s. 543–555. 17 Rabe, K. – Hurd, S. – Anzueto, A. – Barnes, P. – Buist, S. – Calverley, P., et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 2007, 176, s. 532–555. 18 Suissa, S. – Barnes, P.: Inhaled corticosteroids in COPD: the case against. Eur Respir J, 2009, 34, s. 13–16. 19 White, W. B., et al.: ATS 2011, P E71. 20 Wouters, E. F. M., et al.: J Clin Endocrinol Metab, 2012, 97 (9), s. E1720– –E1725.

ACTA MEDICINAE 2/2013 ALERGOLOGIE, PNEUMOLOGIE Kompletní literatura

Atopický ekzém – co nového v léčbě? Prim. MUDr. Štěpánka Čapková Dermatologické oddělení pro děti, FN Motol, Praha RNDr. Dana Nováková Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol, Praha 1 Paller, A. S. – Mancini, A. J.: Hurwitz clinical pediatric dermatology. Fourth edition multimedia on line. Elsevier Saunders, 2011, s. 624. 2 Bieber, T. – Cork, M. – Reitamo, S.: Atopic dermatitis: a candidate for disease-modifying strategy. Allergy, 2012, 67, s. 969–975. 3 Benáková, N.: Atopická dermatitida v roce 2009. Čes-slov Derm, 2009, 84, s. 65–86. 4 Baron, S. E. – Cohen, S. N. – Archer, C. B.: Guidance on the diagnosis and clinical management of atopic eczema. Clinical and Experimental Dermatology, 2012, 37, s. 7–12. 5 Akdis, C. A. – Akdis, M. – Bierber, T., et al.: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinilcal Imunology / American Academy of Allergy,

6 7 8 9

sthma and Immunology / PRACTALL Consensus Report. J Allergy Clin A Immunol, 2006, 118, s. 152–169. Ring, J. – Alomar, A. – Bieber, T., et al.: Guidelines for treatment of atopic eczema (atopic dermatitis) Part I. JEADV, 2012, 26, s.1045–1060. Ring, J. – Alomar, A. – Bieber, T., et al.: Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. JEADV, 2012, 26, s. 1176–1193. Hoare, C. – Li Wan Po, A. – Wiliams, H.: Systematic review of tretments for atopic eczema. Health Technol Assess, 2000. Darsow, U. – Wollenberg, A. – Simon, D., et al.: ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. JEADV, 2010, 24, s. 317–328.

Kontaktní ekzém – kontaktní alergeny doc. MUDr. Eliška Dastychová, CSc. I. dermatovenerologická klinika LF MU a FN u sv. Anny v Brně 1 Beckmann, B. – Ippen, H.: Teebaum-Öl. Dermatose, 1998, 46, s. 120–124. 2 Camarasa, J. G.: Contact dermatitis to ketoprofen. Contact Dermatitis, 1985, 12, s. 120–122. 3 Cavelier, C. – Foussereau J.: Kontaktalergie gegen Metalle und deren Slze. Teil II. Nickel, Kobalt, Quecksilber und Palladium. Dermatosen in Beruf und Umwelt, 1995, 43, s. 152–162. 4 Coz, Ch. J. L. – Bottlaender, A. – Scrivener, J. N. – Santinelli, F. – Cribier, B. J. – Heid, E. – Grosshans, E. M.: Photocontact dermatitis from ketoprofen and tiaprofenic acid: Cross-reactivity sutdy in 12 consecutive patients. Contact Dermatitis, 1998, 38, s. 245–252. 5 Dastychová, E.: Nežádoucí účinky extern obsahujících ketoprofen. Čs Derm, 2000, 75, s. 51–55. 6 Dooms-Goossens, A. – Andersen, K. E. – Brandao, F. M. – Bruynzeel, D. – Burrows, D. – Camarasa, J. – Ducombs, G. – Frosch, P. – Hannuksela, M. – Lachapelle, J. M. – Lathi, A. – Menné, A. – Wahlberg, J. E. – Wilkinson, J. D.: Corticosteroid contact allergy: an EECDRG multicentre study. Contact Dermatitis, 1996, 35, s. 40–44. 7 Foussereau, J.: An epidemiological study of contact allergy to 5-chloro-3-methylisothiazolone 3-methyl-isothiazolone in Strasbourg. Contact Dermatitis, 1990, 22, s. 68–70. 8 Gebhardt, M. – Wollina, U.: Kutane Nebenwirkungen nichtsteroidaler Antiflogistika. Z Rheumatol, 1995, 54, s. 405–412. 9 Greig, J. E. – Thoo, S. L. – Carson, Ch. F. – Riley, T. V.: Allergic contact dermatitis following use of a tea tree oil hand-wash not due to tea tree oil. Contact Dermatitis, 1999, 41, s. 354. 10 Groot, A. C.: Airborne allergic contact dermatitis from Tea Tree Oil. Contact Dermatitis, 1996, 35, s. 304–305. 11 Groot, A. C. – Frosch, P. J.: Averse reactions to fragrances. A clinical review. Contact Dermatitis, 1997, 36, s. 57–86. 12 Kränke B.: Allergisierende Potenz von Teebaum-Öl. Hautarzt, 1997, 48, s. 203–204. 13 Lehmann, P. – Werner, A. – Bäuerle, G. – Breit, R. – Frosch, P. – Fuchs, T. – Günter, G. – Neumann, N. J. – Schaller, J. – Schulze-Dirks,

A. – Vieluf, D. – Wilhelm, P.: Coricosteroid contact dermatitis: Result of a multicenter study from the German Contact Allergy Group. Dermatosen, 1997, 45, s. 116–120. 14 Mozzanica, N. – Pigatto, P. D.: Contact and photocontact allergy to ketoprofen: Clinical and experimental study. Contact Dermatitis, 1990, 23, s. 336–340. 15 Rietschel, R. L. – Fowler, J. F., jr.: Fischer’s Contact dermatitis, 2008, s. 275–278, 287–288, 670–681, 393–404. 16 Semrádová, V. – Dastychová, E. – Navrátilová, Z.: Kontaktní alergie na kortikosteroidy. Čs Derm, 1999, 74, s. 113–117. 17 Semrádová, V. – Dastychová, E.: Polyvalent contact allergy to corticosteroids: A report of two cases. JEADV, 2001, 15, s. 350–353. 18 Urbanček, S.: Alergény štandardnej série. In: Urbanček, S. – Dastychová, E. – Buchvald, D. – Vocilková, A.: Kontaktné alergény v pracovnom a životnom prostredí, 2006, s. 41–73. 19 Uter, W. – Lessmann, H. – Geier, J. – Schnuch, A.: Contact allergy to ingredients of hair cosmetics in female hairdressers and clients — an 8-year analysis of IVDK data. Contact Dermatitis, 2003, 49, s. 236–240. 20 Uter, W. – Hegewald, J. – Aberer, W. – Ayala, F. – Bircher, A. J. – Brach, J. – Coenraads, P.-J. – Schuttellar, M.-L. A. – Elsner, P. – Fartasch, M. – Mahler, V. – Fortina, A. B. – Frosch, P. J. – Fusch, T. – Johansen, J. D. – Menné, T. – Jolanou, R. – Krêcisz, B. – Kiec-Swierczynka, M. – Larese, F. – Orton, D. – Peserico, A. – Rantanen, T. – Schnuch, A.: The European standard series in 9 European countries, 2002/2003 — First results of the European Surveillance Systém on Contact Allergies. Contact dermatitis, 2005, 53, s. 136–145. 21 Wilkinson, S. M.: Hypersensitivity to topical corticosteroids. Clin Exp Derm, 1994, 19, s. 1–11. 22 Wilkinson, S. M. – Hollis, S. – Beck, M. H.: Reaktionen auf andere Kortikosteroide bei Patienten mit allergischer Kontaktdermatitis infolge Hydrocortison. Z Hautkr, 1995, 70, s. 368–372. 23 The ESSCA Writing Group: The European Surveillance System of Contact Alleries (ESSCA): results of patch rating the standard series, 2004. JEADV, 2008, 22, s. 174–181.


Léčba atopické dermatitidy v přehledu MUDr. Radek Litvik Kožní oddělení FN Ostrava 1 Litvik, R.: Atopický ekzém dospělého věku. In: Dermatologie v kazuistikách. Praha, Mladá fronta, 2008, s. 187–194. 2 Litvik, R.: Úloha kožní bariéry u atopické dermatitidy. Farmakoterapie, 2008, s. 11–21. 3 Proksch, E.: The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol, 2008, 21, s. 75–80. 4 Meibach, H. I. – Surber, Ch.: Topical Corticosteroids. Basel, Karger, 1992. 5 Litvik, R.: Tacrolimus v koncentraci 0,03 % a 0,1 % ve formě masti. Farmakoterapie, 2008, s. 5–10. 6 Simpson, E. L. – Hanifin, J. M.: Atopic dermatitis. J Am Acad Dermatol, 2005, 53, s. 115–128. 7 Hanifin, J. M. – Cooper, K. D., et al.: Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines“. J Am Acad Dermatol, 2004, 50, s. 391–404. 8 Jung, T. – Stingl, G.: Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights. J Allergy Clin Immunol, 2008, 122, s. 1074–1081.

9 Benáková, N.: Atopická dermatitida. In: Léčba atopické dermatitidy v novém milleniu. Praha, Astellas Pharma, 2005, s. 3–6. 10 Polášková, S.: Proč může selhat léčba u dětí s atopickou dermatitidou. Farmakoterapie, 2008, s. 32–35. 11 Barbaud, A., et al.: Interest in an emollient containing pentyl rhamnoside in the management of xerosis and atopic skin. Cosmetic Dermatology, 2008, 21, s. 647–651. 12 Cork, M. J., et al.: J Allergy Clin Immunol, 2006, 118, s. 3–21. 13 Leung, D. Y. M. – Soter, N. A.: J Am Acad Dermatol, 2001, 44 (dopl.), s. S1–12. 14 Cork, M., et al.: Dermatology Update. Montreal, Kanada, 6.–7. 11. 2003. 15 ISAAC Steering Committee: Lancet, 1998, 351, s. 1225–1232. 16 Bieber, T.: N Engl J Med, 2008, 358, s. 1483–1494. 17 Beattie, P. E. – Lewis-Jones, M. S.: Br J Dermatol, 2006, 155, s. 145–151. 18 Spergel, J. M.: Am J Clin Dermatol, 2008, 9, s. 233–244. 19 Cork, M. J., et al.: Epidermal barrier dysfunction in atopic dermatitis. In: Rawlings, A. V. – Leyden, J. J. (eds.): Skin Moisturization. London, Informa Healthcare, 2009 (v tisku).

Role vitaminu D u chronických zánětlivých onemocnění MUDr. Jana Čepová, Ph.D., MBA | MUDr. Margareta Beyerová | Ing. Eva Klapková, Ph.D. | Ing. Marta Pechová | prof. MUDr. Richard Průša, CSc. Ústav lékařské chemie a klinické biochemie, 2. LF UK a FN v Motole, Praha 1 Nevoral, J.: Cílený screening celiakie. Postgraduální medicína, 2010, 76, s. 452. 2 Kohout, P.: Celiakie. Postgraduální medicína, 2010, 82, s. 463–477. 3 Novotná, B.: Vitamin D – imunita, alergie a astma. Medical Tribune, 2012, 5. 4 Krejsek, J. – Kopecký, O.: Klinická imunologie. NUCLEUS HK, 2004. 5 Holick, M. F.: The Vitamin D solution. Hudson Street Press, USA, 2011. 6 Holick, M. F.: Vitamin D Deficiency. New Engl J Med, 2007, 357, s. 266–281. 7 IOF Releases New Position Statement on Vitamin D Reccommendations for Older Adults, Florencie, 2010, www.nutritionhorizon.com. 8 Čepová, J. – Kolářová, J. – Pechová, M. – Kotaška, K. – Průša, R.: Kazuistiky

z osteologické ambulance. Interní medicína pro praxi, 2012, 14, 2, s. 78–80. 9 Čepová, J. – Pechová, M. – Beyerová, M.: Kazuistiky z osteologické ambulance. Farmakoterapie – klinická praxe, 2012, 8. 10 Brouwer-Brolsma, E. M. – Bischoff-Ferrari, H. A., et al.: Vitamin D: do we get enough? Osteoporosis Int, 2012, s00198-012-2231-3. 11 Palička, V.: Vitamin D a jeho role (nejen) v osteologii. Interní medicína pro praxi, 2011, 13 (10), s. 383–387. 12 Raška, I.: Vitamin D v prevenci onemocnění? Medicína po promoci, 2012, 4. 13 Kvapil, M.: Diabetologie 2012. Triton, 2012. 14 Čepová, J.: Vitamin D ve zdraví a nemoci, 13. Bergmeyerova konference. Labor Aktuell, 2012, 2.

Doporučené postupy v léčbě astmatu bronchiale MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha 1 Global Initiative for Astma (GINA). GINA workshop report: Global strategy for astma management and prevention. http://www.ginasthma.com. 2 Banks, E. D. – Jalloul, A.: Occupational astma, work-related astma and reactive airways dysfunction syndrome. Curr Opin Pulm Med, 2007, 13, s. 131–136. 3 Wenzel, S. E. – Covar, R.: Update in astma 2005. Am J Respir Crit Care Med, 2006, 173, s. 698–706. 4 Turner, S.: Exhaled nitric oxide in the diagnosis and management of astma. Curr Opin Allergy Clin Immunol, 2008, 8, s. 70–76. 5 Michils, A. – Baldassarre, S. – Van Muylem, A.: Exhaled nitric oxide and astma kontrol: A longidutinal study in unselected patiens. Eur Respir J, 2008, 31, s. 539–546.

6 Sutherland, E. R. – Martin, R. J.: Astma and Atypical Bacterial Infec tion. Chest, 2007, 132, s. 1962–1966. 7 Moore, W. C. – Peters, S. P.: Update in Astma 2006. Am J Respir Crit Care Med, 2007, 175, s. 649–654. 8 Tamesis, G. P. – Krawiec, M. E.: Heterogenity in response to astma medications. Curr Opin Allergy Clin Immunol, 2007, 7, s. 185–189. 9 Holgate, S. – Casale, T. – Wenzel, S. – Bousquet, J. – Deniz, Y. – Reisner, C.: The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol, 2005, 115, s. 459–465. 11 Aubier, M. – Buhl, R. – Ekstrom, T. – Ostinelli, J. – van Schayck, C.P. – Selroos, O. – Haughney, J.: Comparison of two twice-daily doses of


budesonide/formoterol maintance and reliever therapy. Eur Repir J, 2010, 36, s. 524–530. 11 Kašák, V.: Kontrola astmatu a exacerbací. Medicína po promoci, 2010, 11, s. 69–73.

12 Ekerljung, L. – Bossios, A. – Lotvall, J. – Olin, A. C. – Ronmark, E.: Multi-symptom asthma as an indication of disease severity in epidemiology. Eur Repir J, 2011, 38, s. 825–832. 13 Pauk, N.: Současný pohled na postavení LABA v terapii astmatu. Farmakoterapie, 2010, 6, s. 449–452.

Rinosinusitidy: od praktického lékaře do specializované péče ORL nebo alergologie? MUDr. Jan Pokorný, CSc. DG Centrum Ostrava, ORL 1 Markalous, B. – Charvát, F., et al.: Zobrazení hlavy. Triton, 2006, 658 s.

2 Kuchynková, Z.: Nosní polypy. Galén, 2003, 100 s.

Využití salinických roztoků v léčbě onemocnění horních cest dýchacích MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha 1 Middleton, P. G. – Pollard, K. A. – Wheatley, J. R.: Hypertonic saline alters ion transport across the human airway epithelium. Eur Respir J, 2001, 17, s. 195–199. 2 Talbot, A. R. – Herr, T. M. – Parsons, D. S.: Mucociliary clearance and buffered hypertonic saline solution. Laryngoscope, 1997, 107, s. 500–503. 3 Greiff, L. – Andersson, M. – Wollmer, P. – Persson, C. G.: Hypertonic saline increases secretory and exudative responsiveness of human nasal airway in vivo. Eur Respir J, 2003, 21, s. 308–312. 4 Kim, C. H. – Hyun, S. M. – Eun, A. Y. – Lee, J. G. – Yoon, J. H.: Effect of hypo-, iso- and hypertonic saline irrigation on secretory mucins and morphology of cultured human nasal epithelial cells. Acta Otolaryngol, 2005, 125, s. 1296–1300. 5 Kim, J. Y. – Hong, Y. S. – Choi, S. H. – Yoon, Y. H. – Moon, S. W. – Lee, S. W.: Effect of hypertonic saline on apoptosis of polymorphonuclear cells. J Surg Res, 2012, 178, s. 401–408. 6 Han, C. – Choi, S. H. – Yoon, Y. H., et al.: Hypertonic saline downregulate the production level of lipopolysaccharide-induced migration inhibitory factor in THP-1 cells. J Korean Surg Soc, 2012, 82, s. 1–7. 7 Garavello, W. – Romagnoli, M. – Sordo, L. – Gaini, R. M. – Di Berardino, C. – Angrisano, A.: Hypersaline nasal irrigation in children with symptomatic seasonal allergic rhinitis: A randomized study. Pediatr Allergy Immunol, 2003, 14, s. 140–143. 8 Garavello, W. – Romagnoli, M. – Gaini, R. M.: Hypertonic or isotonic

saline for allergic rhinitis in children. Pediatr Allergy Immunol, 2005, 16, s. 91–92. 9 Shoseyov, D. – Bibi, H. – Shai, P. – Shoseyov, N. – Shazberg, G. – Hurvitz, H.: Treatment with hypertonic saline versus normal saline nasal wash of pediatric chronic sinusitis. J Allergy Clin Immunol, 1998, 101, s. 602–605. 10 Taccariello, M. – Parikh, A. – Darby, Y. – Scadding, G.: Nasal douching as a valuable adjunct in the management of chronic rhinosinusitis. Rhinology, 1999, 37, s. 29–32. 11 Rabago, D. – Pasic, T. – Zgierska, A. – Mundt, M. – Barrett, B. – Maberry, R.: The efficacy of hypertonic saline nasal irrigation for chronic sinonasal symptoms. Otolaryngol Head Neck Surg, 2005, 133, s. 3–8. 12 Adappa, N. D. – Wei, C. C. – Palmer, J. N.: Nasal irrigation with or with out drugs: the evidence. Curr Opin Otolaryngol Head Neck Surg, 2012, 20, s. 53–57. 13 Harvey, R. – Hannan, S. A. – Badia, L. – Scadding, G.: Nasal saline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Database Syst Rev, 2007, CD006394. 14 Friedman, M. – Hamilton, C. – Samuelson, C. G., et al.: Dead Sea salt irrigations vs saline irrigations with nasal steroids for symptomatic treatment of chronic rhinosinusitis: A randomized, prospective double-blind study. Int Forum Allergy Rhinol, 2012, 2, s. 252–257. 15 Rabago, D. – Zgierska, A.: Saline nasal irrigation for upper respiratory conditions. Am Fam Physician, 2009, 80, s. 1117–1119.

Kardiovaskulární bezpečnost indakaterolu v léčbě chronické obstrukční plicní nemoci Prim. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie Nemocnice Na Bulovce a 3. LF UK Praha 1 Kašák, V.: Indacaterol – první inhalační β2-agonista s ultradlouhodobým účinkem (ultra-LABA) pro léčbu CHOPN. Farmakoterapie, 2010, 6, 1, s. 40–49. 2 Zindr, V.: Bezpečnost indakaterolu v ročních studiích. Stud Pneumol Phtiseol, 2011, 71 (4), s. 171–178. 3 Khnidri, S. – Sabo, R. – Hartus, S. –Jennings, S. – Drollmann, A. F.: A thorough QT study on the effect of indacaterol on cardiac safety in healthy subjects. Am J Respir Crit Care Med, 2009, 179, A2463.

4 Chapman, K. R. – Rennard, S. I. – Dogra, A. – Owen, R. – Larsen, C. – Kamer, B.: Long-term safety and efficacy of indacaterol, a novel long-acting beta2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest, 2011, 140 (1), s. 68–75. 5 Dahl, R. – Chung, K. F. – Buhl, R., et al.: Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax, 2010, 65, s. 473–479. 7 Buhl, R. – Dunn, L. J. – Disdier, C. – Larsen, C. – Amos, C. – Henley,


M. – Kamer, B.: Eur Respir J, 201, 38, s. 797–803. 8 Donohue, J. F. – Fogarty, C. – Lotvall, J., et al.: Once-daily bronchodilators for chronic obstructive pulmonary disease disease: indacaterol versus tiotropium. Am J Respir Crit Care Med, 2010, 182, s. 155–162.

9 Worth, H. – Chung, K. F. – Felser, J. M. – Hu, H. – Rueegg, P.: Car dio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respiratory Medicine, 2011, 105, s. 571–579.

Novinky v léčbě karcinomu plic prof. MUDr. Jana Skřičková, CSc. | MUDr. Marcela Tomíšková | MUDr. Bohdan Kadlec | MUDr. Lenka Jakubíková, Ph.D. | MUDr. Jana Špaldová Klinika nemocí plicních a tuberkulózy LF MU a FN Brno doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz LF a PF MU Brno 1 Bonomi, P.: Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer, 2003, 41, s. 43–48. 2 Cappuzzo, F. – Ciuleanu, T. – Stelmakh, L., et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 2010, 11, s. 521–529. 3 Ciuleanu, T. – Brodowicz, T. – Zielinski, C., et al.: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, 2009, 374, s. 1432–1440. 4 Duffield, E. L. – Watkins, C. L. – Armour, A. A. – Fukuoka, M.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 2009, 361, s. 947–957. 5 Giroux, D. J. – Rami-Porta, R. – Chansky, K., et al.: The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol, 2009, 4, s. 679–683. 6 Cheng, S. – Evans, W. K. – Stys-Norman, D. – Shepherd, F. A.: Chemotherapy for relapsed small cell lungcancer: a systematic review and practice guideline. J Thorac Oncol, 2007, 2, s. 348–354. 7 Kim, E. S. – Hirsch, V. – Mok, T., et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer: a randomised Phase III trial (INTEREST). Lancet, 2008, 372, s. 1809–1818. 8 Kwak, E. L. – Bang, Y. J. – Camidge, D. R., et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 2010, 363, s. 1693–1703. 9 Lynch, T. J. – Bell, D. W. – Sordella, R., et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350, s. 2129–2139. 10 Miller, V. A. – O’Connor, P. – Soh, C., et al.: A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol, 2009, 27, s. 18. 11 Murray, N. – Turrisi, A. T.: A review of first-line treatment for small-cell lung cancer. J Thorac Oncol, 2006, 1, s. 270–278. 12 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): nonsmall cell lung cancer, verze 2. 2012 [online]. Dostupné z: www.nccn.com [vyhledáno 20. 10. 2011]. 13 NCCN Clinical Praktice Guidelines in Oncology: Small cell lung cancer. NCCN National Comprehensive Cancer Network, verze 1. 2008, 2007, www.nccn.org, 24–25. 14 Niho, S. – Kubota, K. – Yoh, K., et al.: Clinical outcome of chemora diation therapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion. J Thorac Oncol, 2008, 3, s. 723–727. 15 Patel, S. – MacDonald, O. K. – Suntharalingam, M.: Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer, 2009, 115, s. 842–850. 16 Paz-Ares, L. – de Marinis, F., et al.: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for

advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol, 2012, 13, s. 247–255. 17 Pešek, M., et al.: Bronchogenní karcinom. Praha, Galén, 2002. 18 Pešek, M. – Skřičková, J. – Kolek, V., et al.: Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. Stud Pneumol Phtiseol, 2009, 69, s. 62–68. 19 Pešek, M.: Nemalobuněčný karcin plic. EUNI. http://www.euni.cz/tema. php? 20 Pijls-Johannesma, M. – De Ruysscher, D. – Vansteenkiste, J., et al.: Timing of chemoradiotherapy in patients with limited stage small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev, 2007, 33, s. 461–473. 21 Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol, 2009, 27, s. 1227–1234. 22 Sculier, J. – Pand Moro-Sibilot, D.: First-and second-line therapy for advanced non-small-cell lung cancer. Eur Respir J, 2009, 33, s. 915–930. 23 Shaw, A. T. – Yeap, B. Y. – Solomon, B., et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol, 2011, 12, s. 1004–1012. 24 Shepherd, F. A. – Evans, W. K. – Feld, R., et al.: Adjutant chemotherapy following surgical resection for small-cell carcinoma of thelung. J Clin Oncol, 1988, 6, s. 832–838. 25 Shepherd, F. A. – Pereira, J. R. – Ciuleanu, T., et al.: Erlotinib in pre viously treated non-small-cell lung cancer. N Engl J Med, 2005, 353, s. 123–132. 26 Schneider, B. J.: Management of recurrent small cell lung cancer. J Natl Compr Canc Netw, 2008, 6, s. 323–331. 27 Simon, M. – Argiris, A. – Murren, J. R.: Progress in the therapy of small-cell lung cancer. Crit Rev Oncol Hematol, 2004, 49, s. 119–133. 28 Skřičková, J. – Kolek, V., et al.: Základy moderní pneumoonkologie. Maxdorf, Praha, 2012, s. 490. 29 Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448, s. 561–566. 30 Soda, M. – Takada, S. – Takeuchi, K., et al.: A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA, 2008, 105, s. 19893–19897. 31 Wong, D. W. – Leung, E. L. – So, K. K., et al.: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009, 115, s. 1723–1733. 32 Yang, J. CH. – Schuler, M. – Yamamoto, N. – O’Byrne, K. – Hirsh, V. – Tony Mok, T., et al.: LUX-Lung 3: a randomized, open-label, Phase III study of afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol, 2012, 30 (dopl.; abstrakt LBA7500). 33 Zatloukal, P. – Petruželka, L.: Karcinom plic. Praha, Grada, 2001.


Chronická obstrukční plicní nemoc MUDr. Lucie Cwiková Městská nemocnice Ostrava-Fifejdy 1 Kolek, V. – Kašák, V. – Vašáková, M.: Pneumologie. Maxdorf, 2011, s. 552.

Flutikazon furoát v léčbě alergické rýmy MUDr. Ester Seberová RESPIRAL, s. r. o., Plzeň 1 Strachan, D. – Sibbald, B., et al.: Worldwide variation of prevalence of symptoms of allergic rhinoconjunctivitis in children (ISAAC). Pediatr Allergy Immunol, 1997, 8, s. 161–176. 2 Bousquet, et al.: ARIA 2008 Update. Allergy, 2008, 63, s. 8–160. 3 Salter, M., et al.: GW685698-enhanced afinity for glucocorticoid receptor: celular and in vivo pharmacology, prezentováno na: XXV Congres of EAACI, Viena, 2006, abstrakt 781.

4 Salter, M., et al.: Fluticason furouat-enhanced celular and tissue protection with a new selective glucocorticoid antagonist. AAACI, Philadelphia, 2006. 5 Allen, A., et al.: Tolerability, safety and pharmacocinetics and bioavailibility of INSFF in healthy subjects. ACAAI, Philadelphia, 2006. 6 Fuad, M. – Kimberly, A., et al.: Nasal ocular reflex and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol, 2008, 100, s. 194–199.

Léčba pacienta IFN-β-1b (Betaferonem) MUDr. Magdaléna Hladíková, Ph.D. Neurologická klinika LF MU a FN Brno 1 Mendes, A. − Sá, M. J.: Classical immunomodulatory therapy in multiple sclerosis: How it acts, how it works. Arq Neuropsiquiatr, 2011, 69, s. 536–543. 2 The IFN-β Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 1993, 43, s. 655–661. 3 European Study Group on Interferon β-1b in Secondary Progressive MS: Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet, 1998, 3523, s. 1491–1497. 4 Kappos, L. − Polman, C. H., et al.: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 2006, 67, s. 1242–1249. 5 Kappos, L. − Freedman, M. S., et al.: Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year followup analysis of the BENEFIT study. Lancet, 2007, 370, s. 389–397.

6 Edan, G. − Kappos, L., et al.: Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 8-year observational extension of the phase 3 BENEFIT trial. Mult Scler, 2011, 10 (dopl.). 7 Durelli, L. − Verdun, E., et al.: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet, 2002, 359, s. 1453–1460. 8 O‘Connor, P. − Filippi, M., et al.: 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol, 2009, 8, s. 889–897. 9 Cadavid, D. − Wolansky, L. J., et al.: Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology, 2009, 72, s. 1976–1983. 10 Polman, C. H. − Bertolotto, A., et al.: Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol, 2010, 9, s. 740–750.

Využití certolizumab pegolu v léčbě aktivní revmatoidní artritidy MUDr. David Suchý, PhD. Oddělení klinické farmakologie FN Plzeň 1 Venkovský, J.: Certolizumab pegol v léčbě revmatoidní artritidy. Remedia, 2009, 19, s. 308–311. 2 Zeman, J.: Certolizumab a léčba revmatoidní artritidy. Klin Farmakol Farm, 2011, 25, s. 76–78. 3 Strojil, J. – Ciferská, H.: Certolizumab pegol. Klin Farmakol Farm, 2010, 24, s. 155–160. 4 Fleischmann, R. – Vencovsky, J. – van Vollenhoven, R. F., et al.: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis, 2009, 68, s. 805–811. 5 Keystone, E. C. – Fleischmann, R. – Smolen, J., et al.: Sustained

efficacy of certolizumab pegol added to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA): 2-year results from the RAPID 1 trial. Ann Rheum Dis, 2009, 68, s. 237. 6 Smolen, J. – Landewé, R. B. – Mease, P., et al.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis, 2009, 68, s. 797–804. 7 Olejárová, M.: Bezpečnost a účinnost certolizumab pegolu v léčbě revmatoidní artritidy. Farmakoterapie, 2011, 7, s. 335–341. 8 Mariette, X. – van Vollenhoven, R. F. – Bykerk, V. P., et al.: Safety update on certolizumab pegol in patiens with active RA with long term exposure. Arthritis Rheum, 2012, 10, s. 221.


Účinná léčba abataceptem v první linii u pacientky s diabetem mellitem I. typu a s revmatoidní artritidou MUDr. Petr Kopsa Revmatologické a rehabilitační oddělení Thomayerovy nemocnice, Praha 1 Schiff, M. – Bessete, L., et al.: Evaluation of abatacept in biologic-naive patients with active rheumatoid arthritis. Clin Rheumatol, 2010, 29, s. 583–591. 2 Weinblatt, M. – Combe, B., et. al.: Safety of the selective costimula tion modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs. Arthritis & Rheumatism, 2006, 54, s. 2807–2816. 3 Schiff, M. – Keiseman, M. – Codding, C., et al.: Clinical response and tolerability to abatacept in patients with rheumatoid arthritis pre viously treated with infliximab or abatacept: open-label extension of

the ATTEST Study. Ann Rheum Dis, 2011, 70, s. 2003–2007. 4 Kremer, J. M. – Russell, A. S., et al.: Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis, 2011, 70, s. 1826–1830. 5 Orban, T. – Bundy, B., et al.: Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet, 2011, doi: 10.1016/ S0140-6736(11)60886-6.

Subkutánní interferon beta-1a v léčbě roztroušené sklerózy MUDr. Iva Okáčová | doc. MUDr. Pavel Štourač, Ph.D. Neurologická klinika LF MU a FN Brno, CEITEC – Středoevropský technologický institut MU Brno 1 Havrdová, E., et al.: Roztroušená skleróza. In: Neuroimunologie. Maxdorf, 2001, s. 150–151. 2 Bednařík, J. – Amber, Z. – Růžička, E., et al.: Roztroušená skleróza. In: Klinická neurologie, část speciální I. Triton, 2010, s. 509–510. 3 Kappos, L. – Polman, C. H. – Freedman, M. S., et al.: Treatment with interferon b-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 2006, 67, s. 1242–1249. 4 Štourač, P.: Imunomodulační léčba roztroušené sklerózy mozkomíšní v klinických a zobrazovacích parametrech. Cesk Slov Neurol N, 2012, 75, s. 404–410. 5 Horáková, D.: Klinicky izolovaný syndrom a prognostické markery u roztroušené sklerózy. Proč léčit včas? Neurol. pro praxi, 2008, 9, s. 215–217. 6 Havrdová, E.: Roztroušená skleróza. Cesk a Slov Neurol Neurochir, 2008, 71, s. 121–132. 7 The IFNβ Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNβ Multiple Sclerosis Study Group. Neurology, 1993, 43, s. 655–661. 8 Jacobs, L. D. – Cookfair, D. L. – Rudick, R. A., et al.: Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol, 1996, 39, s. 285–294. 9 PRISMS study group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by interferon β-1a in Subcutaneously in Multiple Sclerosis) Study Group. Lancet, 1998, 352, s. 1498–1504.

10 Jacobs, L. D. – Beck, R. W. – Simon, J. H., et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Eng J Med, 2000, 343, s. 898–904. 11 Comi, G. – Filippi, M. – Barkof, F., et al.: Effect of early treatment on conversion to definite multiple sclerosis: A randomized study. Lancet, 2001, 357, s. 1576–1582. 12 Horáková, D.: Léčba klinicky izolovaného syndromu a remitentní roztroušené sklerózy – aktuální doporučení zohledňující nové etiopatogenetické poznatky. Neurol pro praxi, 2010, 13, s. 8–11. 13 Kappos, L. – Freedman, M. S. – Polman, C. H. – Edan, G. – Hartung, H. P. – Miller, D. H. – Montalbán, X. – Barkhof, F. – Radu, E. W. – Metzig, C. – Bauer, L. – Lanius, V. – Sandbrink, R. – Pohl, C. – BENEFIT Study Group: Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol, 2009, 8, s. 987–997. 14 Souhrn údajů o přípravku, SUKL, Interferon beta-1a, http://www.ema. europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf, vyhledáno dne 14. 12. 2012. 15 Cohen, J. A. – Barkhof, M. – Comi, G. – Hartung, H. P. – Khatri, B. – Montalban, X., et al.: TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Eng J Med, 2010, 362, s. 402–415. 16 Panitch, H. – Goodin, D. S. – Francis, G. – Chang, P. – Coyle, P. K. – O‘Connor, P., et al.: Randomized komparative study of interferon beta 1a treatment regiment in MS: the EVIDENCE trial. Neurology, 2002, 59, s. 1496–1506.

Systémová léčba osteolýzy indukované nádorem MUDr. Simona Paulíková | prof. MUDr. Jiří Petera Ph.D. | MUDr. Adam Paulík LF UK a Klinika onkologie a radioterapie FN Hradec Králové 1 Coleman, R, E.: Metastatic bone disease: Clinical features, pathophysio logy and treatement strategie. Cancor Treat Rev, 2001, 27, s. 165–176. 2 Wardley, A. M.: Bone disease in cancer: a growing health problem. In: Bone disease in cancer. Abstract book of the congress. Itálie, Benátky, 24.–25. 6. 2006.

3 Holubec, L. – Matějka, V. M.: Význam PET/CT pro diagnostiku a kontrolu léčby nemocných s kostními metastázami z pohledu klinické onkologie. Edukační sborník XXXV. Brněnských onkologických dní, 2011, s. 263–264. 4 Kolář, J.: Metastázy do skeletu. Radiodiagnostika, 2005, svazek 51, č. 6.


5 Křístek, J.: Perkutánní cementoplastika osteolytických metastáz do skeletu. Edukační sborník XXXV. Brněnských onkologických dní, 2011, s. 265–266. 6 Hortobagyi, G. N.: Novel approaches to the management of bone metastase. Semin Oncol, 2003, 30 (dopl. 16), s. 161–166. 7 Hortobagyi, G. N.: Treatement of brest cancor. N Engl J Med, 1998, 339, s. 974–984. 8 Fleisch, H.: Bisphosphonates: A new vlase druha in disease of bone and kalcium metabolism. In: Brunner, K. W. – Fleish, H. – Senn, H. J.,

eds.: Bisphosphonates and Tumor Osteolysis. Německo, Berlín, Springer-Verlag, 1989, s. 1–28. 9 Parker, C. – Heindrich, D. – O´Sulivan, L. M., et al.: Overall surfoval benefit of radium-223 chloride (Alpharadin) in the treatement of patiens with symptomatic bone metastase on satration-resistantn prostate cancor: A phase III randomized trial (ALSYMPCA). ECCO-ESMO, 2011, abstrakt 1LBA. 10 Barton, M. K.: Denosumab an option for patients with bone metastasis from breast cancer. CA Cancer J Clin, 2011, květen, s. 135–136.

Antitrombotická léčba – léčba apixabanem MUDr. Hynek Poul Oddělení hematologie a transfuziologie Nemocnice Pelhřimov, p. o. 1 Ericsson, B. I. – Quinlan, D. J. – Weitz, J. I.: Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet, 2009, 48, s. 1–22. 2 Turpie, A. G. G.: Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterio scler Thromb Vasc Biol, 2007, 27, s. 1238–1247. 3 Ansell, J. J.: Factor Xa or thrombin: is factor Xa a better target? Thromb Haemost, 2007, 5, s. 60–64. 4 Larsen, M. R., et al.: APROPOS=Apixaban PROphylaxis in Patients undergoing total knee replacement Surgery. J Thromb Haemost, 2007, 5, s. 2368–2375. 5 SPC Eliquis. 6 Raskob, G. E. – Gallus, A. S. – Pineo, G. F. – Chen, D. – Ramirez, L. M. – Wright, R. T. – Larsen, M. R.: Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br, 2012, 94, s. 257–264. 7 Wang et al.: Prezentováno na WCCPT 2008. Poster T2TH071. 8 Barrett, Y. C. – Wang, Z. – Frost, C. – Shenker, A.: Clinical laboratory

measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost, 2010, 104, s. 1263–1271. 9 Gogarten, W., et al.: Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol, 2010, 27, s. 999–1015. 10 Eikelboom, J. W. – O‘Donnell, M. – Yusuf, S. – Diaz, R. – Flaker, G. – Hart, R. – Hohnloser, S. – Joyner, C. – Lawrence, J. – Pais, P. – Pogue, J. – Synhorst, D. – Connolly, S. J.: Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J, 2010, 159, s. 348–353. 11 Yates, S. W.: Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. Hosp Pract (Minneap), 2011, 39, s. 7–16. 12 Granger, C. B.: ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 15, 365, s. 981–992. 13 Wong, P. C. – Pinto, D. J. P. – Zhang, D.: Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis, 2011, 31, s. 478–492. Publikováno on-line 13. 2. 2011, doi: 10.1007/s11239-011-0551-3.

Novinky ve fekální bakterioterapii prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha 1 Eiseman, B. – Silen, W. – Bascom, G. S. – Kauvar, A. J.: Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery, 1958, 44, s. 854–859. 2 Kelly, C. P. – LaMont, J. T.: Clostridium difficile – more difficult than ever. NEJM, 2008, 359, s. 1932–1940. 3 Gough, E. – Shaikh, H. – Magnes, A. R.: Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clinical Infectious Diseases, 2011, 53, s. 994–1002. 4 Kelly, C. P.: Fecal microbiota transplantation – an old therapy comes of age. NEJM, 2013, publikováno před tiskem, doi: 10.1056/ NEJMe1214816. 5 van Nood, E. – Vrieze, A. – Nieuwdorp, M. – Fuentes, S. – Zoetendal, E. G. – de Vos, W. M. – Visser, C. E. – Kuijper, E. J. – Bartelsman, J. F. W. M. – Tijssen, J. G. P. – Speelman, P. – Dijkgraaf, M. G. W. – Keller, J. J.: Duodenal infusion of donor feces for recurrent Clostridium difficile. NEJM, 2013, publikováno před tiskem, doi: 10.1056/NEJMoa1205037. 6 Petrof, E. O. – Gloor, G. – Vanner, S. J. – Weese, S. J. – Carter, D. – Daig neault, M. C. – Brown, E. M. – Schroerter, K. – Allen-Vercoe, E.: Stool substitute transplant therapy for the eradication of Clostridium difficile

infection: “RePOOPulating” the gut. Microbiome, 2013, 1, s. 3. 7 Tvede, M. – Rask-Madsen, J.: Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six pacients. Lancet, 1989, 1, s. 1156–1160. 8 Upadhyay, V. – Poroyko, V. – Kim, T. – Devkota, S. – Fu, S. – Liu, D. – Tumanov, A. V. – Koroleva, E. P. – Deng, L. – Nagler, C. – Chang, E. B. – Tang, H. – Fu, Y-X.: Lymphotoxin regulates commensal responses to enable diet-induced obesity. Nature Immunology, 2012, 13, s. 947–953. 9 Smith, M. I. – Yatsunenko, T. – Manary, M. J. – Trehan, I. – Mkakosya, R. – Cheng, J. – Kau, A. L. – Rich, S. S. – Concannon, P. – Mychaleckyj, J. C. – Liu, J. – Houpt, E. – Li, J. V. – Holmes, E. – Nicholson, J. – Knights, D. – Ursell, L. K. – Knight, R. – Gordon, J. I.: Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science, 2013, 339, s. 548–554. 10 Quince, C. – Lundin, E. E. – Andreasson, A. N. – Greco, D. – Rafter, J. – Talley, N. J. – Agreus, L. – Andersson, A. F. – Engstrand, L. – D‘Amato, M.: The impact of Crohn‘s disease genes on healthy human gut microbiota: a pilot study. Gut, 2013, publikováno před tiskem, doi:10.1136/ gutjnl-2012-304214.


2013 Kompletní literatura ALERGOLOGIE, PNEUMOLOGIE

Recommend Documents